Evidence map›Paper›PMID 32017367›Full record

ArticleJournal of thrombosis and haemostasis : JTH2020

C-terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities.

Atsuki Yamashita, Yuqi Zhang, Michel F Sanner, John H Griffin, Laurent O Mosnier

Open access · bronzeAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Atsuki YamashitaDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Yuqi ZhangDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Michel F SannerDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
John H GriffinDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Laurent O MosnierDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0003-1195-964X
Scripps Research Institute · US

Funding

Structure and Function of Protein CR01HL052246 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI GRIFFIN, JOHN H · 2005 to 2017
$9.6M
Regulation of Protein C PathwaysR01HL142975 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI GRIFFIN, JOHN H, MOSNIER, LAURENT OLIVIER · 2018 to 2025
$7.3M
Structure-function of cytoprotective coagulation proteases and their receptorsR01HL104165 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI MOSNIER, LAURENT OLIVIER · 2011 to 2024
$6.1M
In-silico prediction of protein-peptide interactions.R01GM096888 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI SANNER, MICHEL F. · 2011 to 2023
$5.1M
STRUCTURE/FUNCTION OF PROTEIN CR37HL052246 · NHLBI · SCRIPPS RESEARCH INSTITUTE · PI GRIFFIN, JOHN H · 1995 to 2004
$2.9M
Novel functions of Thrombin Activatable Fibrinolysis Inhibitor (TAFI)R01HL148096 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI MOSNIER, LAURENT OLIVIER · 2020 to 2023
$2.6M
Discovery of novel vascular therapies targeting PfEMP1-mediated cytoadhesion in severe malariaR01HL130678 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI LAVSTSEN, THOMAS, MOSNIER, LAURENT OLIVIER · 2015 to 2018
$2.0M
NHLBI NIH HHS R01 HL052246NHLBI NIH HHS R01 HL104165NHLBI NIH HHS R01 HL130678NHLBI NIH HHS R01 HL142975NHLBI NIH HHS R01 HL148096NHLBI NIH HHS R37 HL052246NIGMS NIH HHS GM09888NIGMS NIH HHS R01 GM096888
6 · The paper itself

Abstract

backgroundActivated protein C (APC) is an important homeostatic blood coagulation protease that conveys anticoagulant and cytoprotective activities. Proteolytic inactivation of factors Va and VIIIa facilitated by cofactor protein S is responsible for APC's anticoagulant effects, whereas cytoprotective effects of APC involve primarily the endothelial protein C receptor (EPCR), protease activated receptor (PAR)1 and PAR3.

objectiveTo date, several binding exosites in the protease domain of APC have been identified that contribute to APC's interaction with its substrates but potential contributions of the C-terminus of the light chain have not been studied in detail.

methodsSite-directed Ala-scanning mutagenesis of six positively charged residues within G142-L155 was used to characterize their contributions to APC's anticoagulant and cytoprotective activities. RESULTS AND

conclusionsK151 was involved in protein S dependent-anticoagulant activity of APC with some contribution of K150. 3D structural analysis supported that these two residues were exposed in an extended protein S binding site on one face of APC. Both K150 and K151 were important for PAR1 and PAR3 cleavage by APC, suggesting that this region may also mediate interactions with PARs. Accordingly, APC's cytoprotective activity as determined by endothelial barrier protection was impaired by Ala substitutions of these residues. Thus, both K150 and K151 are involved in APC's anticoagulant and cytoprotective activities. The differential contribution of K150 relative to K151 for protein S-dependent anticoagulant activity and PAR cleavage highlights that binding exosites for protein S binding and for PAR cleavage in the C-terminal region of APC's light chain overlap.

Indexed as

AnticoagulantsProtein CBlood CoagulationFactor VaHumansReceptor, PAR-1AnticoagulantsFactor VaProtein CReceptor, PAR-1activated protein Canticoagulant activitycytoprotective activityprotease activated receptorprotein S

Identifiers

PMID32017367
PMCPMC7380734
OpenAlexW3004607614

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.